Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Clinical Trials
12
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2014
Active, not recruiting
2
16.7%
Completed
6
50.0%
Recruiting
3
25.0%
Terminated
1
8.3%
No approval data available
- Corvus Pharmaceuticals is approaching a critical Phase 2 data readout for its lead candidate soquelitinib, which could significantly reshape investor assessment of the company. - The promising Phase 1 safety profile for soquelitinib provides a foundation for the upcoming efficacy data in atopic dermatitis. - Updates on potential partnering or M&A interest are being closely watched alongside the clinical data milestones. - The company currently reports minimal revenue and ongoing losses, making the soquelitinib outcomes a high-stakes event for the investment case.
- Enterome has appointed Dr. Mehrdad Mobasher, former Chief Medical Officer at BeiGene and current IFLI Executive Partner, to its Board of Directors to strengthen leadership in developing OncoMimics immunotherapies. - The company's lead candidate EO2463 has shown positive Phase 2 interim data in low tumor-burden follicular lymphoma and received FDA Fast Track designation for the watch and wait setting. - IFLI, a key investor that contributed up to $9 million in Enterome's $19 million funding round, continues to support the development of OncoMimics therapies targeting B-cell lymphomas. - Enterome's OncoMimics platform represents a novel immunotherapy approach that induces rapid expansion of memory T-cells, with three candidates showing positive early Phase 2 data across blood cancers and solid tumors.
- TRexBio closed an oversubscribed $50 million Series B extension to support clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells for inflammatory diseases. - The company completed the single ascending dose portion of its Phase 1a/b trial for TRB-061 in atopic dermatitis, with multiple ascending dose testing currently underway and results expected by 2027. - Funding will also advance two additional preclinical programs, TRB-071 and TRB-081, toward Phase 1 trials in 2027 for multiple inflammatory and autoimmune conditions. - The financing attracted new investors including Janus Henderson Investors and Balyasny Asset Management, alongside existing backers like Eli Lilly and Pfizer Ventures.
- Over 100 pharmaceutical companies are actively developing more than 100 pipeline drugs for eczema treatment, representing a significant expansion in therapeutic options for this chronic inflammatory skin condition. - Sanofi's Amlitelimab achieved all primary and key secondary endpoints in the Phase III COAST 1 study, demonstrating statistically significant skin clearance in patients with moderate-to-severe atopic dermatitis at Week 24. - The pipeline features diverse mechanisms of action including OX40 ligand inhibitors, interleukin receptor antagonists, and STAT6 transcription factor degraders, with approximately 10+ drugs in late-stage development. - Recent clinical milestones include positive Phase I results for Concerto Biosciences' ENS-002 topical biotherapeutic and FDA clearance for Sitryx Therapeutics' SYX-5219 Phase Ib trial.
- Corvus Pharmaceuticals presented final Phase 1/1b data for soquelitinib at ASH 2025, showing median progression-free survival of 6.2 months and overall survival of 28.1 months in the 200 mg twice-daily cohort. - The ITK inhibitor demonstrated objective responses in 9 of 24 patients with 1-3 prior therapies, including 6 complete responses and 3 partial responses, with no dose-limiting toxicities observed. - The results support the ongoing registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, addressing a significant unmet medical need where current treatments yield poor outcomes. - Soquelitinib's novel mechanism affects T cell differentiation by promoting Th1 cells while blocking Th2 and Th17 development, with potential applications beyond oncology in immune and inflammatory diseases.
- Corvus Pharmaceuticals presented interim data from a Phase 1b/2 trial showing that ciforadenant combined with ipilimumab and nivolumab achieved a 34% deep response rate in metastatic renal cell cancer patients. - The triplet therapy demonstrated a 46% objective response rate and 11.04-month median progression-free survival in a challenging patient population with unfavorable disease characteristics. - The treatment was well-tolerated with a safety profile consistent with the established ipilimumab and nivolumab combination, supporting further development of adenosine A2a receptor inhibition in cancer immunotherapy. - Nineteen patients remain on therapy with potential to achieve additional deep responses, providing opportunity for longer-term efficacy assessment.
- DelveInsight's 2025 pipeline report reveals over 20 pharmaceutical companies are actively developing 22+ interleukin-2 inhibitor drugs across various clinical stages. - The FDA granted fast track designation to rezpegaldesleukin for moderate to severe atopic dermatitis in February 2025, while nemvaleukin development was discontinued following failed Phase III trial results. - Leading pipeline candidates include Soquelitinib in Phase III for relapsed/refractory PTCL and multiple Phase II programs targeting autoimmune diseases and cancer indications. - The growing prevalence of autoimmune diseases and organ transplant procedures is driving increased demand for IL-2 inhibitors due to their role in preventing immune rejection.
- Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment. - The randomized, double-blinded, placebo-controlled trial will evaluate multiple dosing regimens over 12 weeks, with patient enrollment expected to begin in Q3 2025. - Soquelitinib is an investigational oral ITK inhibitor developed by Corvus Pharmaceuticals, representing a novel immunotherapy approach for immune diseases. - Phase 1b data is anticipated in 2026, while Corvus continues parallel development in the U.S. with plans for a Phase 2 trial by year-end.
• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.
- NIH/NIAID has launched a Phase 2 clinical trial of Corvus Pharmaceuticals' soquelitinib for autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease typically manifesting by age two. - The trial will enroll up to 30 patients aged 16 or older with confirmed ALPS-FAS, evaluating soquelitinib's ability to reduce splenomegaly and lymph node volumes while improving cytopenias. - Soquelitinib, an oral ITK inhibitor, aims to address immune dysregulation in T cells that characterizes ALPS, expanding its clinical development beyond ongoing trials in peripheral T cell lymphoma and atopic dermatitis.
